Difference between revisions of "Mapatumumab (HGS-ETR1)"
Jump to navigation
Jump to search
m |
m |
||
| (One intermediate revision by one other user not shown) | |||
| Line 1: | Line 1: | ||
| − | =Mechanism of action= | + | ==Mechanism of action== |
Monoclonal antibody directed against the tumour necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) | Monoclonal antibody directed against the tumour necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) | ||
| + | |||
| + | ==Also known as== | ||
| + | *'''Code name:''' HGS-ETR1 | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
[[Category:Intravenous medications]] | [[Category:Intravenous medications]] | ||
| − | + | ||
[[Category:Anti-TRAIL-R1 antibodies]] | [[Category:Anti-TRAIL-R1 antibodies]] | ||
[[Category:Investigational drugs]] | [[Category:Investigational drugs]] | ||
Latest revision as of 13:56, 16 December 2020
Mechanism of action
Monoclonal antibody directed against the tumour necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1)
Also known as
- Code name: HGS-ETR1